Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Discovery of novel therapeutic opportunities for EOC is important for the improvement of clinical outcome of the patients. Emerging evidence is suggesting that epithelial-mesenchymal transition (EMT) plays a crucial role in the aggressiveness in EOC including increasing migration and invasion ability, contributing to chemoresistance and cancer stem cell populations. Targeting EMT in EOC thus offers an attractive therapeutic option.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / metabolism*
-
Carcinoma, Ovarian Epithelial
-
Drug Delivery Systems / trends*
-
Drug Resistance, Neoplasm / drug effects
-
Drug Resistance, Neoplasm / physiology
-
Epithelial-Mesenchymal Transition / drug effects
-
Epithelial-Mesenchymal Transition / physiology*
-
Female
-
Humans
-
Neoplasm Invasiveness / genetics
-
Neoplasms, Glandular and Epithelial / drug therapy
-
Neoplasms, Glandular and Epithelial / metabolism*
-
Neoplasms, Glandular and Epithelial / pathology
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / metabolism*
-
Ovarian Neoplasms / pathology